Background: The rise in antibiotic-resistant pathogens underscores the urgent need to fortify the existing weak antimicrobial agents. Novel antimicrobials are products of microbes, as two-thirds of the currently available antibiotics are sourced from them. Understanding the killing rate of the potential antibiotic-producing microbe is essential during the development of antimicrobials. Our preliminary investigation identified a potential antibiotic-producing Bacillus subtilis subsp. subtilis168.
Method: In this study, we investigated the inhibitory activity and time-kill kinetics of the extract of Bacillus subtilis subsp. subtilis 168 against some selected pathogenic strains. Broth microdilution and time-kill assays were used to evaluate the antibacterial activity of the extract. Data analysis was performed with the Kruska-Wallis H test using the statistical software Stata 16.
Results:The extract showed antibacterial activity against Staphylococcus aureus (ATCC 25923) (MIC = 28.70 mg/mL), Escherichia coli (ATCC 25922) (MIC = 28.70 mg/mL), Pseudomonas aeruginosa(ATCC 27853) (MIC = 28.70 mg/mL) and K. pneuminiae (MIC = 14.35 mg/mL). At 0.5 × MIC, the extract was bacteriostatic against all the test bacteria for the 24-hour incubation period. At the 1 x MIC (28.70 mg/mL), the extract achieved bactericidal endpoints (≥99.9% killing) of 3.87 Log10 CFU/mL reduction of S. aureus (ATCC 25923) at 6 h incubation, 6.81 Log10 CFU/mL reduction of E. coli (ATCC 25922) at 6 h (1 x MIC: 28.70 mg/mL), 6.87 Log10 CFU/mL reduction of P. aeruginosa (ATCC 27853) at 8 h (1 x MIC: 28.70 mg/mL), and 6.90 Log10 CFU/mL reduction at 8 h incubation of K. pneumoniae (1 x MIC: 14.35 mg/mL). At 2 x MIC, the extract showed bactericidal endpoints of at least 3 Log10 CFU/mL reduction of all the test strains at lower exposure times. The killing kinetics of the extract against each test strain were statistically significant (P ≤ 0.05) at 0.5 x MIC, 1 x MIC, and 2 x MIC.
Conclusion: The killing kinetics of the extract demonstrated both time- and concentration-dependent bactericidal activity against the selected panel of pathogenic strains, achieving a minimum three-log reduction at 1 × MIC and 2 × MIC within 2-8 h exposure. These findings suggest the promising therapeutic potential of the extract.